Literature DB >> 23248042

Successful treatment of POLG-related mitochondrial epilepsy with antiepileptic drugs and low glycaemic index diet.

Mika H Martikainen1, Markku Päivärinta, Satu Jääskeläinen, Kari Majamaa.   

Abstract

Epilepsy is a common manifestation of mitochondrial disease associated with mutations of the mitochondrial polymerase γ (POLG). Prognosis of mitochondrial epilepsy is often poor and there are few reports of successful treatment of POLG-related epilepsy. We describe a 26-year-old woman who experienced severe headache during a three-day period, followed by symptoms of visual flashing, speech difficulty, and generalised seizures. EEG recording showed non-convulsive status epilepticus (left occipital area) and brain MRI revealed parieto-occipital T2-hyperintensities. Visual aura and aphasia persisted despite antiepileptic medication with phenytoin, oxcarbazepine, and levetiracetam. Mitochondrial disorder was clinically suspected and a homozygous c.2243G>C mutation (p.Trp748Ser) was discovered in the POLG1 gene. The patient was then set on a low glycaemic index treatment (LGIT) variant of the ketogenic diet, after which the headaches, aphasia, and visual aura progressively improved and disappeared. She returned home two weeks after onset of symptoms and has not had further seizures. She continues to receive levetiracetam monotherapy and LGIT. We conclude that, at least for this patient, the combination of three antiepileptic drugs and LGIT is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23248042     DOI: 10.1684/epd.2012.0543

Source DB:  PubMed          Journal:  Epileptic Disord        ISSN: 1294-9361            Impact factor:   1.819


  17 in total

Review 1.  Ketogenic diets in patients with inherited metabolic disorders.

Authors:  S Scholl-Bürgi; A Höller; K Pichler; M Michel; E Haberlandt; D Karall
Journal:  J Inherit Metab Dis       Date:  2015-06-25       Impact factor: 4.982

2.  Ketogenic Diets for Adults With Highly Refractory Epilepsy.

Authors:  Tanya J W McDonald; Mackenzie C Cervenka
Journal:  Epilepsy Curr       Date:  2017 Nov-Dec       Impact factor: 7.500

Review 3.  Nutritional interventions in primary mitochondrial disorders: Developing an evidence base.

Authors:  Kathryn M Camp; Danuta Krotoski; Melissa A Parisi; Katrina A Gwinn; Bruce H Cohen; Christine S Cox; Gregory M Enns; Marni J Falk; Amy C Goldstein; Rashmi Gopal-Srivastava; Gráinne S Gorman; Stephen P Hersh; Michio Hirano; Freddie Ann Hoffman; Amel Karaa; Erin L MacLeod; Robert McFarland; Charles Mohan; Andrew E Mulberg; Joanne C Odenkirchen; Sumit Parikh; Patricia J Rutherford; Shawne K Suggs-Anderson; W H Wilson Tang; Jerry Vockley; Lynne A Wolfe; Steven Yannicelli; Philip E Yeske; Paul M Coates
Journal:  Mol Genet Metab       Date:  2016-09-20       Impact factor: 4.797

4.  Treatment of mitochondrial disorders.

Authors:  Sreenivas Avula; Sumit Parikh; Scott Demarest; Jonathan Kurz; Andrea Gropman
Journal:  Curr Treat Options Neurol       Date:  2014-06       Impact factor: 3.598

Review 5.  Ketogenic Diets for Adult Neurological Disorders.

Authors:  Tanya J W McDonald; Mackenzie C Cervenka
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

Review 6.  Current and Emerging Clinical Treatment in Mitochondrial Disease.

Authors:  Rory J Tinker; Albert Z Lim; Renae J Stefanetti; Robert McFarland
Journal:  Mol Diagn Ther       Date:  2021-03-01       Impact factor: 4.074

7.  ND2 mutation with minimal coenzyme-Q responsive manifestations.

Authors:  Josef Finsterer; Sinda Zarrouk-Mahjoub
Journal:  Mol Genet Metab Rep       Date:  2017-01-20

Review 8.  POLG-related disorders and their neurological manifestations.

Authors:  Shamima Rahman; William C Copeland
Journal:  Nat Rev Neurol       Date:  2019-01       Impact factor: 42.937

Review 9.  Mitochondrial disease: genetics and management.

Authors:  Yi Shiau Ng; Doug M Turnbull
Journal:  J Neurol       Date:  2015-08-28       Impact factor: 4.849

10.  Mitochondrial Myopathy, Encephalopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS) due to a m.10158T>C ND3 Mutation with a Normal Muscle Biopsy.

Authors:  Josef Finsterer; Sinda Zarrouk-Mahjoub
Journal:  Intern Med       Date:  2017-09-06       Impact factor: 1.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.